Oct 03, 2019 GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said yesterday that they filed a supplemental New Drug Application with the FDA, seeking an additional indication for GSK’s Trelegy Ellipta inhaler for the treatment of asthma in adults. The once-daily, single-inhaler triple-therapy device received FDA approval for the treatment of chronic obstructive pulmonary disease in September 2017. MIT Microbiome Club. 672 likes 1 talking about this. The MIT Microbiome Club provides a space at MIT dedicated to the exploration of the vibrant field of human microbiome studies. Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is used to treat chronic obstructive pulmonary disease (COPD). It is less popular than other comparable drugs. There are currently no generic alternatives to Trelegy Ellipta. GoodRx has partnered with InsideRx. Biologics are different from traditional systemic drugs that impact the entire immune system. Biologics only target specific parts of the immune system. The biologics used to treat psoriatic disease block the action of a specific type of immune cell called a T-cell.
- electron-packager ~/Work/Trelify Trelify --platform=darwin --arch=all --version=0.36.9 --out=/Users/martinkase/Work/Trelify --icon=/Users/martinkase/Work/Trelify/logo.icns -—app-bundle-id=com.kasemartin.trelify --app-category-type=public.app-category.business -—sign-entitlements=child.plist -—sign= 5DARBK48ZS -—sign-entitlements-inherit=parent.plist --helper-bundle-id=com.kasemartin.trelify.helper --extend-info=info.plist --overwrite
Trelify